Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.37B 2.11B 1.95B 1.77B 3.31B 225B 3.36B 23.49B 9.3B 118B 8.88B 8.69B 371B P/E 2026 *
-177x
P/E 2027 * 36.2x
Enterprise Value 2.37B 2.11B 1.95B 1.77B 3.31B 225B 3.36B 23.49B 9.3B 118B 8.88B 8.69B 371B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 1.74x
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week+7.44%
Current month-5.44%
1 month-5.98%
3 months-11.90%
6 months-18.21%
Current year-18.11%
1 week 37.76
Extreme 37.765
42.09
1 month 37.54
Extreme 37.54
44.93
Current year 37.54
Extreme 37.54
59.68
1 year 37.54
Extreme 37.54
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 2005-12-21
Director of Finance/CFO 67 2021-08-22
Compliance Officer 63 2011-12-31
Director TitleAgeSince
Director/Board Member 64 2005-12-21
Chairman 81 2016-08-09
Director/Board Member 80 2010-11-15
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Chief Technology Officer

4,097 0.0073%
8/12/26 Exercice

Chief Financial Officer

3,104 0.0055%
8/12/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%+7.44%-22.96%+69.58% 2.37B
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 636B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.31%+2.69%+31.02%+69.20% 400.67B
Weighted average by Cap. -1.35%+2.66%+40.99%+79.75%

Financials

2026 *2027 *
Net sales 874M 780M 721M 653M 1.22B 82.97B 1.24B 8.68B 3.44B 43.47B 3.28B 3.21B 137B 1.36B 1.21B 1.12B 1.02B 1.9B 129B 1.93B 13.49B 5.34B 67.57B 5.1B 4.99B 213B
Net income -13.38M -11.95M -11.04M -10M -18.72M -1.27B -19.03M -133M -52.59M -666M -50.22M -49.15M -2.1B 65.41M 58.41M 53.96M 48.9M 91.49M 6.21B 93M 649M 257M 3.25B 245M 240M 10.26B
Net Debt - -
Projected Income Statement - Annual - Supernus Pharmaceuticals, Inc.
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
26-10-23 US$40.70 -3.26% 1,159,336
26-10-22 US$42.07 +2.09% 937,419
26-10-21 US$41.21 -0.05% 1,006,298
26-10-20 US$41.23 +3.49% 1,240,345
26-10-19 US$39.84 +5.17% 1,509,140
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
40.70USD
Average target price
60.50USD
Spread / Average Target
+48.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Supernus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SUPN Stock